Lisomucil cough 750 mg/15 ml 200 ml syrup

Lisomucil cough 750 mg/15 ml 200 ml syrup is a mucolytic syrup specifically formulated for the symptomatic treatment of productive cough and catarrh in adults. Thanks to the presence of carbocysteine , an active ingredient known for its effectiveness in thinning mucus and promoting its elimination, Lisomucil syrup helps to clear the airways, improving breathing and reducing the discomfort caused by respiratory tract conditions such as bronchitis, colds and other acute and chronic respiratory diseases .

Available in a 200 ml bottle , Lisomucil cough 750 mg/15 ml is indicated for those looking for an effective and easy-to-take cough medicine . Its formulation is available with or without sugar , to adapt to different needs, including patients who need to control their sugar intake. The product acts quickly, reducing the viscosity of the mucus and facilitating its expulsion through the cough reflex, offering rapid relief from the symptoms of productive cough .

Lisomucil cough is particularly indicated for the treatment of cough and catarrh in adults, thanks to its targeted action on bronchial secretions. The presence of carbocysteine ​​makes it an ideal syrup for adults for those who suffer from productive cough and need an effective mucolytic to improve the quality of breathing and promote the well-being of the respiratory system. Choose Lisomucil cough 750 mg/15 ml 200 ml syrup for a reliable and proven effective symptomatic cough therapy .

ACTIVE INGREDIENTS

Active ingredients contained in Lisomucil cough 750 mg/15 ml 200 ml syrup - What is the active ingredient of Lisomucil cough 750 mg/15 ml 200 ml syrup?

1 ml of syrup contains: Active ingredient : carbocysteine ​​50 mg. Excipients with known effect : Sugar syrup: sucrose, methyl parahydroxybenzoate (E218), aromatic elixir (ethanol 82%). Sugar-free syrup: methyl parahydroxybenzoate, sodium. For the full list of excipients, see section 6.1.

EXCIPIENTS

Composition of Lisomucil cough 750 mg/15 ml 200 ml syrup - What does Lisomucil cough 750 mg/15 ml 200 ml syrup contain?

LISOMUCIL TOSSE MUCOLYTIC syrup with sugar: sucrose, methyl parahydroxybenzoate, caramel powder, aromatic elixir (ethanol 82%), cinnamon essence, sodium hydroxide, purified water. LISOMUCIL TOSSE MUCOLYTIC syrup without sugar: glycerol, hydroxyethylcellulose, sodium saccharin, sodium methyl parahydroxybenzoate, caramel powder, flavouring, sodium hydroxide, purified water.

DIRECTIONS

Therapeutic indications Lisomucil cough 750 mg/15 ml 200 ml syrup - Why is Lisomucil cough 750 mg/15 ml 200 ml syrup used? What is it used for?

Symptomatic therapy of respiratory tract conditions accompanied by cough and catarrh in adults.

CONTRAINDICATIONS AND SIDE EFFECTS

Contraindications Lisomucil cough 750 mg/15 ml 200 ml syrup - When should Lisomucil cough 750 mg/15 ml 200 ml syrup not be used?

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Active gastroduodenal ulcer. Pregnancy and breastfeeding. Children and adolescents.

DOSAGE

Quantity and method of taking Lisomucil cough 750 mg/15 ml 200 ml syrup - How to take Lisomucil cough 750 mg/15 ml 200 ml syrup?

The recommended dosage is as follows: 1 measuring spoon or 1 tablespoon (15 ml of product equal to 750 mg of carbocysteine) 3 times a day with an interval of 8 hours between one intake and the other. The maximum recommended duration of treatment is 5 days. Treatment for longer periods can be carried out, according to the doctor's judgment.

CONSERVATION

Storage Lisomucil cough 750 mg/15 ml 200 ml syrup - How is Lisomucil cough 750 mg/15 ml 200 ml syrup stored?

LISOMUCIL TOSSE MUCOLITICO syrup with sugar: store below 25°C. LISOMUCIL TOSSE MUCOLITICO syrup without sugar : this medicine does not require any storage conditions.

WARNINGS

Warnings Lisomucil cough 750 mg/15 ml 200 ml syrup - About Lisomucil cough 750 mg/15 ml 200 ml syrup it is important to know that:

Gastrointestinal bleeding Cases of gastrointestinal bleeding have been reported with the use of carbocisteine. Caution is advised in the elderly, in patients with a history of gastroduodenal ulcers or in patients taking concomitant medications known to increase the risk of gastrointestinal bleeding. In the event of gastrointestinal bleeding, patients should discontinue treatment with carbocisteine. Asthmatic and debilitated patients Specific precautions are advised in patients with severe respiratory insufficiency, in patients with asthma and a history of bronchospasm, as well as in debilitated patients. The use of carbocisteine ​​causes a decrease in mucus viscosity and an increase in mucus clearance, both through epithelial ciliary activity and the cough reflex. Therefore, an increase in cough and sputum is expected. The use of antitussive drugs inhibits the cough reflex and increases the risk of airway obstruction, due to an increase in mucus accumulation in the airways. Concomitant use of this medicinal product with cough sedatives and/or medicinal products that inhibit bronchial secretion (e.g. anti-muscarinic medicinal products) is not recommended. LISOMUCIL TOSSE MUCOLITICO syrup with sugar contains 6 g of sucrose per 15 ml of syrup (1 measuring spoon or 1 spoon). Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency should not take this medicine. To be taken into consideration in patients with diabetes mellitus. The excipient aromatic elixir of LISOMUCIL TOSSE MUCOLITICO syrup with sugar contains 200 mg of ethyl alcohol (ethanol) per dose of 15 ml (one measuring spoon or spoon) which is equivalent to 4 mg/kg per dose of 15 ml of syrup. The amount of ethyl alcohol in 15 ml of this medicine is equivalent to less than 5 ml of beer or 2 ml of wine. The small amount of alcohol in this medicine will not produce significant effects. For those who play sports, the use of medicines containing ethyl alcohol may cause positive results in anti-doping tests in relation to the limits of alcohol concentration indicated by some sports federations. LISOMUCIL TOSSE MUCOLITICO syrup with sugar and LISOMUCIL TOSSE MUCOLITICO syrup without sugar contain methyl para-hydroxybenzoate which may cause allergic reactions (even delayed). LISOMUCIL TOSSE MUCOLITICO syrup without sugar contains 90 mg of sodium per dose of 15 ml (1 tablespoon) and 270 mg of sodium per dose of 3 tablespoons per day equivalent to 4.5% and 13.5% respectively of the maximum daily intake recommended by the WHO which corresponds to 2 g of sodium for an adult. LISOMUCIL TOSSE MUCOLYTIC syrup with sugar contains less than 1 mmol (23 mg) sodium per 15 ml dose, that is to say essentially 'sodium-free'.

INTERACTIONS

Interactions Lisomucil cough 750 mg/15 ml 200 ml syrup - Which medicines or foods can modify the effect of Lisomucil cough 750 mg/15 ml 200 ml syrup?

At the current state of knowledge, there are no known incompatibilities between the administration of carbocisteine ​​and the most common drugs used in the treatment of upper and lower airway conditions, nor with foods or laboratory tests.

SIDE EFFECTS

Like all medicines, Lisomucil cough 750 mg/15 ml 200 ml syrup can cause side effects - What are the side effects of Lisomucil cough 750 mg/15 ml 200 ml syrup?

Undesirable effects are listed according to the following frequency classification: Very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000); very rare (< 1/10,000), not known (frequency cannot be estimated from the available data). Immune system disorders. Frequency not known: anaphylactic reaction, allergic skin rashes, fixed drug eruption. Gastrointestinal disorders. Very common: diarrhoea, nausea and upper abdominal pain. Frequency not known: epigastric discomfort, vomiting and gastrointestinal bleeding (in which case discontinue treatment and consult your doctor to institute appropriate therapy). Skin and subcutaneous tissue disorders. Frequency not known: bullous dermatitis, Stevens-Johnson syndrome, erythema multiforme, toxic skin eruption, rash. In such cases, discontinue treatment and consult your doctor to institute appropriate therapy. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse.

OVERDOSE

Overdose Lisomucil cough 750 mg/15 ml 200 ml syrup - What are the risks of Lisomucil cough 750 mg/15 ml 200 ml syrup in case of overdose?

Symptoms of overdose include: headache, nausea, diarrhea, gastralgia. Induce vomiting and possibly perform gastric lavage.

PREGNANCY AND BREASTFEEDING

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Lisomucil cough 750 mg/15 ml 200 ml syrup.

LISOMUCIL TOSSE MUCOLYTIC is contraindicated during pregnancy and breastfeeding (see paragraph 4.3). No clinical data are available.

DRIVING AND USE OF MACHINERY

Taking Lisomucil cough 750 mg/15 ml 200 ml syrup before driving or using machines - Does Lisomucil cough 750 mg/15 ml 200 ml syrup affect driving or using machines?

LISOMUCIL TOSSE MUCOLYTIC syrup does not alter the ability to drive vehicles or use machinery.